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ABSTRACT
Romosozumab, a monoclonal anti-sclerostin antibody that has the dual effect of increasing bone formation and decreasing bone
resorption, reduces fracture risk within 12 months. In a post hoc, exploratory analysis, we evaluated the effects of romosozumab after
12 months of denosumab in postmenopausal women with low bonemass who had not received previous osteoporosis therapy. This
phase 2 trial (NCT00896532) enrolled postmenopausal women with a lumbar spine, total hip, or femoral neck T-score ≤ 2.0 and
≥ 3.5. Individuals were randomized to placebo or various romosozumab dosing regimens from baseline to month 24, were re-
randomized to 12 months of denosumab or placebo (months 24–36), and then all received romosozumab 210 mg monthly for
12 months (months 36–48). Results for the overall population have been previously published. Here, we present results for changes
in bonemineral density (BMD) and levels of procollagen type I N-terminal propeptide (P1NP) and β-isomer of the C-terminal telopep-
tide of type I collagen (β-CTX) from a subset of women who were randomized to placebo for 24 months, were re-randomized to
receive denosumab (n= 16) or placebo (n= 12) for 12 months, and then received romosozumab for 12 months. In womenwhowere
randomized to placebo followed by denosumab, romosozumab treatment for 12 months maintained BMD gained during denosu-
mab treatment at the total hip (mean change from end of denosumab treatment of 0.9%) and further increased BMD gains at the
lumbar spine (mean change from end of denosumab treatment of 5.3%). Upon transition to romosozumab (months 36–48), P1NP
and β-CTX levels gradually returned to baseline from their reduced values during denosumab administration. Transitioning to romo-
sozumab after 12 months of denosumab appears to improve lumbar spine BMD and maintain total hip BMD while possibly prevent-
ing the rapid increase in levels of bone turnover markers above baseline expected upon denosumab discontinuation. © 2021 The
Authors. JBMR Plus published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research.
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Introduction
Antiresorptive drugs and bone-forming agents are distinctclasses of therapies for treating patients with osteoporo-
sis.(1) Estrogen receptor activators, bisphosphonates, and deno-
sumab are anti-remodeling drugs that reduce bone resorption
and formation, increase bone mineral density (BMD), improve
bone strength and reduce fracture risk, but they do not restore
the disordered trabecular microarchitecture found in patients
with postmenopausal osteoporosis.(2) In contrast, bone-forming
agents stimulate bone formation, resulting in large increases in
BMD and improved bone structure, and have been shown to
be more effective at reducing fracture risk than oral bisphospho-
nates.(3–7) Based on these data, bone forming agents are recom-
mended as appropriate initial treatment for patients at very high
risk of fracture.(8–10)
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Romosozumab, an anti-sclerostin monoclonal antibody, is a
bone-forming agent with a novel mechanism of action—a dual
effect of activating both modeling-based and remodeling-based
bone formation while reducing bone resorption.(11,12) In
treatment-naïve postmenopausal women with osteoporosis,
romosozumab significantly improved bone mass and reduced
fracture risk compared to placebo or alendronate.(3,13,14) The bene-
fits of the initial treatment with romosozumab for 12 months were
maintained when patients were transitioned to either alendronate
or denosumab.(3,13,15) Some patients who have previously received
antiresorptive therapies might also be candidates for romosozu-
mab. Changes in BMD, estimated bone strength, and levels of
serum bone turnover markers (BTMs) have been evaluated in
patients transitioned from bisphosphonates to romosozumab.(16)
BMD and BTM responses to romosozumab in postmenopausal
women who had taken denosumab for 12 months have also been
reported;(17) however, the women in that report had received
romosozumab for 24 months before they received denosumab.
To address amore common clinical scenario, we report here a post
hoc, exploratory analysis of the effects of transitioning from deno-
sumab to romosozumab in women with low bonemass not previ-
ously treated with romosozumab.
Patients and Methods
Study design and patients
The women in this report were part of the romosozumab phase
2 dose-finding study (NCT00896532; https://www.clinicaltrials.
gov/ct2/show/NCT00896532). This international, multicenter,
randomized, placebo-controlled, parallel-group study and its
extensions had randomized 419 postmenopausal women 55 to
85 years old with low bone mass (T-score of ≤ 2.0 and
≥ 3.5 at the lumbar spine, total hip, or femoral neck) into mul-
tiple arms and interventions; the details have been previously
published.(14,17,18) Briefly, women were randomized to receive
one of five dosing regimens of subcutaneous romosozumab
monthly or every 3 months (n = 261) or to receive one of two
open-label comparators (weekly oral alendronate 70 mg
[n = 51] or daily subcutaneous teriparatide 20 μg [n = 55])
(Figure 1A; Supplemental Figure S1). The remaining 52 women
were randomly assigned to receive subcutaneous placebo
monthly or every 3 months. On completing the 12-month
double-blind treatment period, women in the romosozumab
and placebo groups continued their assigned treatment for an
additional 12 months. At month 24, eligible consenting women
entered a 12-month extension phase and were re-randomized
(1:1) to double-blind treatment with subcutaneous placebo or
subcutaneous denosumab 60 mg every 6 months. Those who
completed the month 24 to month 36 extension period then
entered a 12-month phase where they received open-label sub-
cutaneous romosozumab 210 mg monthly through month 48.
All women were instructed to take calcium (≥1 g) and vitamin
D (≥800 IU) daily throughout the study. In this analysis, we report
the results from a subset of women who were randomized to
receive placebo for 24 months, re-randomized to receive deno-
sumab or placebo for 12 months, and then received romosozu-
mab for 12 months. This provides two treatment groups: one
that received romosozumab after 3 years of placebo (Group 1;
n = 12) and the second group that received placebo for 2 years,
then denosumab for 12 months followed by 12 months of treat-
ment with romosozumab (Group 2; n= 16) (Figure 1B). Only data
from the 28 subjects who entered the month 36 to month
48 romosozumab treatment period are included in the analyses.
One woman in Group 2, although assigned to receive placebo
during months 0 to 12, received romosozumab during this
period. To be consistent with data previously reported from this
study, data for this woman was included in the efficacy but not
the safety analyses.
Study procedures
The study procedures for assessing BMD and BTMs have been
previously published.(14,17,18) Briefly, BMD at the lumbar spine
and proximal femur were evaluated by dual-energy x-ray absorp-
tiometry (DXA; Lunar, GE Medical Systems, Madison, WI, USA or
Hologic, Hologic Inc., Bedford, MA, USA) at baseline (month 0)
and months 3, 6, 12, 18, 24, 30, 36, 39, 42, and 48. BioClinica (pre-
viously known as Synarc; Newark, CA, USA) analyzed the scans
and provided quality control of the individual scans and densi-
tometers. Fasting serum samples were collected and analyzed
to assess levels of procollagen type I N-terminal propeptide
(P1NP) (UniQ P1NP radioimmunoassay [RIA]; Orion Diagnostica
Oy, Espoo, Finland) and β-isomer of the C-terminal telopeptide
of type I collagen (β-CTX) (Serum CrossLaps enzyme-linked
immunosorbent assay [ELISA]; Nordic Bioscience Diagnostics,
A/S, Herlev, Denmark) at baseline through month 36 and then
at months 37, 39, 42, 45, and 48.
Study outcomes
Results for the whole population and for other treatment
sequences have been previously published.(14,17–19) This report
focuses on changes in BMD and P1NP and β-CTX levels in a sub-
set of women who received 12 months of romosozumab either
after 36 months of placebo (Group 1) or after 24 months of pla-
cebo followed by 12 months of denosumab (Group 2).
A nonresponder analysis assessed the proportion of women
with a BMD percentage decrease of >3% at the lumbar spine,
total hip, or femoral neck during four time periods: baseline to
24 months, 24–36 months, 36–48 months, and 24–48 months.
The 3% arbitrary cutoff for response versus nonresponse repre-
sents the approximate least significant change for the lumbar
spine and total hip, as previously reported.(15)
Statistical analysis
Data for all endpoints were summarized descriptively. Percent-
age changes from baseline in BMD are presented as means
and 95% confidence intervals (CIs). Percentage changes from
baseline in P1NP and β-CTX are presented as medians and inter-
quartile ranges. For the nonresponder analysis, number (n) and
percentages of subjects are presented.
Results
Patients and baseline characteristics
Results of this phase 2 study and its extensions have been previ-
ously reported.(14,17,18) This study reports data for months 24 to
48 for the 28 women who entered the month 36 to month
48 romosozumab treatment period (12 women in Group 1 who
received romosozumab after 3 years of placebo; 16 women in
Group 2 who received placebo for 2 years, then denosumab for
12 months followed by 12 months of treatment with romosozu-
mab). Nowomen in Group 1 discontinued the studywhile receiv-
ing romosozumab between month 36 and month 48. Two
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women in Group 2 discontinued the study during this period;
1 due to an adverse event and the other due to withdrawn
consent.
Patient characteristics at baseline (month 0) and month 24 in
the subset of women reported in this analysis were generally
similar between groups (Table 1) with women in Group 2 being
somewhat younger, having fewer years since menopause, and
having higher levels of BTMs as compared to Group 1. Baseline
characteristics for patients included in this analysis were also
similar to those previously reported for the overall phase 2 study
population.(14)
BMD
BMD remained stable at the lumbar spine and decreased mod-
estly in the proximal femur in women who received placebo
for the first 24 months (Figure 2; Table 2). Increases in BMD at
the lumbar spine, total hip, and femoral neck of 9.1%, 4.6%,
and 3.9%, respectively, were observed during the 12-month
therapy (from month 24 to 36) with romosozumab in Group 1
(Figure 2A,C; Supplemental Figure S2A; Table 2). In Group 2, the
average increase in BMDwas 5.5%, 2.8%, and 2.3% at the lumbar
spine, total hip, and femoral neck, respectively, during therapy
with denosumab from month 24 to 36. In these women, lumbar
spine BMD increased an additional 5.3% while taking romosozu-
mab for 12 months for an average cumulative gain of 11.5% over
the 24-month denosumab-to-romosozumab treatment period
(Figure 2B; Table 2). The increase in BMD seen with denosumab
at the total hip was maintained by 12 months of romosozumab;
0.9% mean change from end of denosumab treatment, for a
cumulative gain of 3.8% over the 24-month treatment period
with denosumab and romosozumab (Figure 2D; Table 2). Simi-
larly, the femoral neck BMD increase noted with denosumab
treatment was maintained by 12 months of romosozumab;
Fig. 1. Phase 2 study design. (A) Women were randomized 1:1:1:1:1:1:1:1 to the first 24 months of treatment. Administration of placebo and the various
romosozumab doses was blinded; alendronate and teriparatide were administered open-label. At month 24, women were rerandomized (1:1) within
treatment group to placebo or denosumab (60 mg s.c. Q6M) for 12 months, followed by a 12-month second course of romosozumab 210 mg s.c.
QM. (B) A subset of women who were randomized to receive placebo for 24 months (n = 52), rerandomized to receive denosumab (n = 16) or placebo
(n= 12) for 12 months, and then received romosozumab for 12 months and whose results are presented in this report. aIndividuals transitioned to romo-
sozumab 140 mg QM at month 12, were randomized in the denosumab extension period, completed the study at month 36 and are not included in the
present analysis. bIndividuals completed the study at month 12 and are not included in the present analysis. cOf the 52 women initially randomized to
placebo from months 0 to 24, 18 were rerandomized to receive denosumab and 18 to receive placebo; the remaining 16 discontinued the study. Abbre-
viations: Q3M, every 3 months; Q6M, every 6 months; QD, daily; QM, monthly; QW, weekly; s.c., subcutaneously.
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Table 1. Baseline characteristics of the subset of women who were randomized to placebo for 24 months, denosumab or placebo for
12 months, and then received romosozumab for 12 months
Month 0 baseline Month 24 baseline
Group 1 (n = 12) Group 2 (n = 16) Group 1 (n = 12) Group 2 (n = 16)
Treatment from month 0–24 Placebo Placebo Placebo Placebo
Treatment from month 24–36 Placebo Denosumab 60 mg Q6M Placebo Denosumab 60 mg Q6M
Treatment from month 36–48 Romosozumab 210 mg QM Romosozumab 210 mg QM Romosozumab 210 mg QM Romosozumab 210 mg QM
Age (years), mean  SD 68.2  6.5 63.8  4.1 70.7  6.4 66.1  4.1
Years since menopause,
mean  SD
20.3  9.8 16.9  6.4 22.3  9.8 18.9  6.4
BMD T-score, mean  SD
Lumbar spine 2.3  0.6 2.4  0.4 2.1  0.7 2.4  0.4
Total hip 1.3  0.7 1.1  0.6 1.5  0.7 1.2  0.6
Femoral neck 1.8  0.6 1.6  0.5 1.9  0.6 1.7  0.4
P1NP (μg/L), median (Q1, Q3) 37.0 (33.8, 41.0) 52.4 (44.9, 59.2) 38.2 (30.0, 55.6) 50.0 (40.0, 56.0)
β-CTX (ng/L), median (Q1, Q3) 372.0 (306.0, 415.5) 503.5 (392.5, 635.5) 534.0 (433.5, 692.0) 626.0 (466.0, 833.0)
Notes: Reference ranges for the study are 9.7–92.5 μg/L for P1NP and 16.0–430.0 ng/L for β-CTX. n = number of women enrolled from month 36 to
month 48.
Abbreviations: β-CTX, β-isomer of the C-terminal telopeptide of type I collagen; BMD, bone mineral density; P1NP, procollagen type I N-terminal propep-
tide; Q1, first quartile; Q3, third quartile; Q6M, every 6 months; QM, monthly; SD, standard deviation.
Fig. 2. Percentage change from baseline in lumbar spine and total hip BMD through month 48 for (A,C) placebo-to-placebo-to-romosozumab and (B,D)
placebo-to-denosumab-to-romosozumab. Data reported are for a subset of women who were randomized to receive placebo for 24 months (n = 52),
rerandomized to receive denosumab or placebo for 12 months, and then received romosozumab for 12 months. n = number of women enrolled from
month 36 to month 48. Abbreviations: BMD, bone mineral density; Q6M, every 6 months; QM, monthly.
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1.0% mean increase from end of denosumab treatment, for a
cumulative gain of 3.2% over the last 2 years of the study
(Supplemental Figure S2B; Table 2).
The nonresponder analysis is presented in Table 3. None of
the women who received romosozumab in Group 1 experienced
a decrease in BMD of >3% at the lumbar spine, total hip, or fem-
oral neck. Among the women in Group 2 who received denosu-
mab from months 24 to 36, none had a decrease of >3% at the
lumbar spine or total hip while receiving romosozumab during
months 36–48. However, two of the 13 women in this group
(15.4%) evidenced a decrease of femoral neck BMD of >3%
(a decrease of 3.6% in one and 4.0% in another) while receiving
romosozumab after 12 months of denosumab.
BTMs
Median absolute levels of P1NP and β-CTX are shown in Supple-
mental Table S1 and percentage changes from baseline are shown
Table 2. Mean BMD percentage changes from baseline at the lumbar spine, total hip, and femoral neck
Group 1 (n = 12) Group 2 (n = 16)
Treatment from month 0–24 Placebo Placebo
Treatment from month 24–36 Placebo Denosumab 60 mg Q6M
Treatment from month 36–48 Romosozumab 210 mg QM Romosozumab 210 mg QM
BMD (% change), mean (95% CI)
Lumbar spine
Month 0–24 2.7 (0.2, 5.1) 0.8 (2.8, 1.1)
Month 24–36 0.4 (2.1, 1.4) 5.5 (3.6, 7.4)
Month 36–48 9.1 (6.1, 12.1) 5.3 (3.2, 7.4)
Month 24–48 8.9 (5.5, 12.4) 11.5 (8.8, 14.3)
Total hip
Month 0–24 2.2 (3.6, 0.8) 1.6 (2.7, 0.5)
Month 24–36 0.3 (1.4, 0.8) 2.8 (2.1, 3.6)
Month 36–48 4.6 (2.7, 6.4) 0.9 (0.1, 1.8)
Month 24–48 4.7 (2.7, 6.7) 3.8 (2.6, 5.0)
Femoral neck
Month 0–24 1.3 (2.7, 0.1) 1.8 (3.3, 0.4)
Month 24–36 0.7 (1.7, 0.3) 2.3 (1.0, 3.6)
Month 36–48 3.9 (1.7, 6.1) 1.0 (1.0, 2.9)
Month 24–48 3.1 (0.8, 5.3) 3.2 (1.4, 5.0)
Note: n = number of women enrolled from month 36 to month 48.
Abbreviations: BMD, bone mineral density; CI, confidence interval; Q6M, every 6 months; QM, monthly.
Table 3. Proportion of women who experienced BMD percentage decrease from baseline >3% at the lumbar spine, total hip, and fem-
oral neck
Group 1 (n = 12) Group 2 (n = 16)
Treatment from month 0–24 Placebo Placebo
Treatment from month 24–36 Placebo Denosumab 60 mg Q6M
Treatment from month 36–48 Romosozumab 210 mg QM, n2/n1 (%) Romosozumab 210 mg QM, n2/n1 (%)
Lumbar spine
Month 0–24 0/12 (0) 7/16 (43.8)
Month 24–36 1/12 (8.3) 0/16 (0)
Month 36–48 0/11 (0) 0/13 (0)
Month 24–48 0/10 (0) 0/13 (0)
Total hip
Month 0–24 5/12 (41.7) 4/16 (25.0)
Month 24–36 0/12 (0) 0/16 (0)
Month 36–48 0/11 (0) 0/13 (0)
Month 24–48 0/10 (0) 0/13 (0)
Femoral neck
Month 0–24 3/12 (25.0) 5/16 (31.3)
Month 24–36 1/12 (8.3) 0/16 (0)
Month 36–48 0/11 (0) 2/13 (15.4)
Month 24–48 0/10 (0) 0/13 (0)
Notes: n= number of women enrolled frommonth 36 tomonth 48; n1= number of womenwith an evaluation; n2= number of womenwho experienced
BMD percentage decrease from baseline >3%.
Abbreviations: BMD, bone mineral density; Q6M, every 6 months; QM, every month.
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in Figure 3. While on placebo, P1NP and β-CTX remained largely
unchanged. In women who began romosozumab after 36 months
of placebo, the observed patterns of BTM changes were similar to
those reported(13,14) (Figure 3A,C). During 12 months of denosu-
mab treatment, median serum levels of P1NP and β-CTX decreased
at all measured timepoints (months 24–36) (Figure 3B,D). Upon
transition from denosumab to romosozumab (months 36–48),
BTM levels gradually returned to levels just above baseline by
month 48 for P1NP and to baseline by month 48 for β-CTX
(Figure 3B,D).
Safety
Adverse events that started duringmonths 36 to 48 are shown in
Table 4. The adverse-event profile during months 36 to 48 was
similar to that in the first course of romosozumab 210 mg every
month (month 0 to month 12(14)). Of the 28 women who entered
the month 36 to month 48 romosozumab treatment period
(12 in Group 1; 16 in Group 2), one woman in Group 2 had
received romosozumab during months 0 to 12 of the double-
blind period and data for this woman was excluded from the
safety analysis. Of the remaining 27 patients, adverse events
were reported in 24 women; 12 (100.0%) in Group 1 and
12 (80.0%) in Group 2 experienced adverse events. A serious
adverse event of invasive follicular thyroid carcinoma was
reported in one (6.7%) patient in Group 2. Although not consid-
ered treatment related, the thyroid cancer led to discontinuation
from the study. No fatal events were reported in either group.
Adverse events potentially associated with hypersensitivity
were reported in two women, one in Group 1 and the other in
Group 2. Injection-site reactions, mostly mild in severity, were
reported in two (13.3%) women in Group 2 and malignancy
was reported in one (6.7%) woman in Group 2. Osteoarthritis
was reported in three women; two (16.7%) women in Group
1 and one (6.7%) woman in Group 2. There were no reports of
hyperostosis, hypocalcemia, positively adjudicated osteonecro-
sis of the jaw, or positively adjudicated atypical femur fracture.
Discussion
In this exploratory analysis, transitioning from 12 months of
denosumab to romosozumab for 12 months resulted in a grad-
ual increase in serum markers of bone formation and resorption
to or slightly above baseline levels from the low values observed
while on denosumab. The BMD gain achieved with denosumab
was generally maintained at the proximal femur and increased
by an additional 5.3% at the lumbar spine.
Fig. 3. Percentage changes from baseline in serum P1NP and β-CTX throughmonth 48 for (A,C) placebo-to-placebo-to-romosozumab and (B,D) placebo-
to-denosumab-to-romosozumab. Data reported are for a subset of women who were randomized to receive placebo for 24 months (n = 52), rerando-
mized to receive denosumab or placebo for 12 months, and then received romosozumab for 12 months. n = number of women enrolled from month
36 to month 48. Abbreviations: β-CTX, β-isomer of the C-terminal telopeptide of type I collagen; P1NP, procollagen type I N-terminal propeptide; Q1, first
quartile; Q3, third quartile; Q6M, every 6 months; QM, monthly.
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Some aspects of these results are notable. First, neither the
rapid increase in levels of BTMs to values above baseline nor the
rapid decrease in BMD that accompanies denosumab discontinu-
ationwas observedwhen therapy was switched fromdenosumab
to romosozumab.(20,21) These results differ from those seen upon
transitioning from denosumab to teriparatide where BTMs
increased well above baseline, and BMD in the proximal femur
declined significantly during the first 12 months of teriparatide
therapy.(22) Second, the gains in BMD with 12 months of romoso-
zumab in the group that had previously received 12 months of
denosumab were smaller than those achieved over 12 months
when romosozumab was the first therapy. Smaller increments in
BMDwere also observed with romosozumab therapy in postmen-
opausal women who had previously received bisphosphonate
therapy compared with responses typically observed in those
who had not taken osteoporosis medications.(14,16) Moreover,
the total gain in total hip and femoral neck BMD achieved with
12 months of denosumab followed by 12 months of romosozu-
mab in this study was smaller than that achieved with 12 months
of romosozumab in women who had previously received only
placebo. Finally, increases in BMD over the 24-month sequence
of denosumab followed by romosozumab were smaller (lumbar
spine +11.5%, total hip +3.8%, femoral neck +3.2%) than the
reported changes in women with osteoporosis who received
12 months of romosozumab followed by denosumab for an addi-
tional 12 months in the Fracture Study in Postmenopausal
Women with Osteoporosis (FRAME) (lumbar spine +16.6%, total
hip +8.5%, femoral neck +7.3%).(13)
The observed differences in BMD responses depending upon
the sequence with which romosozumab and denosumab are
given have important clinical implications. Recent studies have
shown associations between current fracture risk and proximal
femur BMD achieved on treatment with alendronate, denosu-
mab, or romosozumab.(23,24) These observations are supported
by the meta-regression analysis showing that therapies that pro-
duce the largest increases in BMD are associated with the great-
est reductions in fracture risk.(25) Collectively, these results
support the use of a bone-forming agent first followed by a
potent antiresorptive drug as an optimal treatment sequence,
particularly for women at very high risk of fracture.(15,26)
The smaller BMD gains observed with romosozumab follow-
ing denosumab are consistent with other studies showing that
changes in BMD both with antiresorptive drugs and teriparatide
are related to baseline levels of bone turnover.(27–29) BTM levels
are routinely lower in women receiving denosumab compared
with pretreatment values.(30,31) Our results are also consistent
with a recent observational study demonstrating smaller BMD
increases with romosozumab in women who had received previ-
ous antiresorptive therapy.(32)
Interpreting the BMD and BTM responses in women transi-
tioning from denosumab to any other therapy is complicated
by the dynamic changes in bone remodeling known to occur
in the several months following denosumab discontinua-
tion.(20,21) The BMD response during the 12 months of romoso-
zumab after denosumab in our study is, at least in relative
terms, greater than is apparent because a significant decrease
in bone density would have been expected upon stopping deno-
sumab without further therapy.(20,21)
The clinical value of the present study is that this is the first
study to evaluate the sequence of denosumab followed by
romosozumab in treatment-naïve postmenopausal women.
Important limitations to our study need to be acknowledged.
The small number of individuals and the post hoc, exploratory
nature of our study precludes firm conclusions about the effec-
tiveness of romosozumab to prevent the rebound in bone remo-
deling and loss of bone density upon discontinuation of
denosumab, and our results should be interpreted with caution.
Additionally, the short duration of denosumab therapy
Table 4. Subject incidence of adverse events during months 36 to 48
Group 1 (n = 12) Group 2 (n = 15)a
Treatment from month 0–24 Placebo Placebo
Treatment from month 24–36 Placebo Denosumab 60 mg Q6M
Treatment from month 36–48 Romosozumab 210 mg QM, n1 (%) Romosozumab 210 mg QM, n1 (%)
All 12 (100.0) 12 (80.0)
Seriousb 0 (0) 1 (6.7)
Leading to study discontinuation 0 (0) 1 (6.7)
Death 0 (0) 0 (0)
Adverse events of interest
Potentially associated with hypersensitivity 1 (8.3) 1 (6.7)
Injection-site reactions 0 (0) 2 (13.3)
Malignancies 0 (0) 1 (6.7)
Osteoarthritis 2 (16.7) 1 (6.7)
Atypical femoral fracturec 0 (0) 0 (0)
Hypocalcemia 0 (0) 0 (0)
Hyperostosis 0 (0) 0 (0)
Osteonecrosis of the jawc 0 (0) 0 (0)
Notes: Only adverse events starting during months 36 to 48 are included. n = number of participants in each treatment group who received at least one
dose of romosozumab during months 36 to 48; n1 = number of participants reporting at least one adverse event.
Abbreviations: Q6M, every 6 months; QM, every month.
aOf the 16 women in Group 2, one had received romosozumab duringmonths 0 to 12 of the double-blind period; data for this woman was excluded from
the safety analysis.
bOne woman in Group 2 had invasive follicular thyroid carcinoma deemed by the investigator not to be related to the study drug; the woman was dis-
continued from the drug and study due to the cancer.
cAll potential events of osteonecrosis of the jaw and atypical femur fracture from the start of the study were retrospectively assessed for adjudication.
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(12 months) before transitioning to romosozumab might not
reflect responses to that of transition after longer exposure to
denosumab. Furthermore, the women in our study had low bone
mass and were not at high risk of fracture and thus might not be
representative of subjects most likely to receive romosozumab
therapy.
In conclusion, romosozumab appears to maintain or improve
the gains in BMD after a 12-month course of denosumab treat-
ment in postmenopausal women with low bone mass, while
levels of BTMs gradually return to baseline levels. The sequence
of romosozumab after denosumab is not as effective in increas-
ing BMD as is the opposite sequence of using romosozumab first.
Larger studies in women at high fracture risk are needed to
determine the true clinical impact and utility of the treatment
sequence of denosumab followed by romosozumab.
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